Form 4: Director Sells Crinetics Pharmaceuticals Stock

Director Rogerio Vivaldi Coelho has sold 3,000 shares of Crinetics Pharmaceuticals, Inc. common stock for $40 per share, executed under a Rule 10b5-1 trading plan.

Summary

• Rogerio Vivaldi Coelho, a Director at Crinetics Pharmaceuticals, Inc., reported a transaction on July 2, 2026.
• The transaction involved the sale of 3,000 shares of common stock.
• The sale was executed at a price of $40.00 per share.
• This sale was conducted automatically under a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2025.
• Following the transaction, the reporting person beneficially owns 19,225 shares of common stock.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the insider sale, although the execution via a Rule 10b5-1 plan mitigates concerns about opportunistic selling.

Negatives

• Director sold a significant number of shares (3,000) of company stock.

Future Outlook

The filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that insider sales, particularly when executed under a pre-arranged trading plan like Rule 10b5-1, are common and can be for various personal financial planning reasons. However, significant sales by directors can sometimes be interpreted by the market as a lack of confidence, depending on the volume and context.

Stakeholder Impact

• Shareholders may view the director's sale of stock negatively, potentially impacting share price in the short term, despite the sale being part of a pre-planned trading strategy.

Key Dates

Recommendation

The filing reports an insider sale executed under a Rule 10b5-1 plan. While insider selling can be a negative signal, the pre-planned nature of this transaction suggests it may be for personal financial management rather than a reflection of negative company outlook. Therefore, a 'hold' recommendation is appropriate pending further company-specific developments.

Keywords

Form 4, SEC Filing, Insider Trading, Stock Sale, Rule 10b5-1, Crinetics Pharmaceuticals, Director Transaction, Beneficial Ownership